Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ: MDGL) has announced participation in two upcoming virtual investor conferences. Management will hold a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, at 9:40 AM EST, and at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 2, 2021, at 11:30 AM EST. The presentations will be webcast live and archived for 90 days on the Madrigal website. The company is focused on developing therapies for cardio-metabolic diseases, particularly NASH, with its lead candidate resmetirom currently in Phase 3 studies.

CONSHOHOCKEN, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with high unmet medical need such as non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming virtual investor conferences:

Evercore ISI 4th Annual HealthCONx Conference 2021

Fireside chat at 9:40 AM EST on Tuesday, November 30, 2021

Piper Sandler 33rd Annual Virtual Healthcare Conference

Fireside chat at 11:30 AM EST on Thursday, December 2, 2021

The presentations will be webcast live and archived recordings will be available for replay in the Events & Presentations section of the Madrigal website for 90 days following the live presentations.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of fatty liver and cardio-metabolic diseases with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR)-β selective agonist that is currently in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO- NAFLD-1, designed to demonstrate multiple benefits in NASH (non-alcoholic steatohepatitis) patients. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

What are the dates of the upcoming investor conferences for Madrigal Pharmaceuticals (MDGL)?

Madrigal Pharmaceuticals will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 2, 2021.

What time will Madrigal Pharmaceuticals present at the Evercore ISI conference?

Madrigal Pharmaceuticals will hold a fireside chat at 9:40 AM EST on November 30, 2021, during the Evercore ISI conference.

How can I watch the Madrigal Pharmaceuticals investor presentations?

The presentations will be webcast live and can be accessed on the Madrigal website, where archived recordings will be available for 90 days.

What is Madrigal Pharmaceuticals focusing on with its lead candidate, resmetirom?

Madrigal Pharmaceuticals is developing resmetirom for treating non-alcoholic steatohepatitis (NASH) and related cardio-metabolic diseases.

What is the significance of the investor conferences for Madrigal Pharmaceuticals (MDGL)?

The investor conferences are significant as they provide an opportunity for Madrigal Pharmaceuticals to showcase its developments and engage with stakeholders about its clinical progress.